Olmesartan Medoxomil Metaprolol Tablet
Description
OLMEROOT-MT 25
Olmesartan Medoxomil 20 mg and Metoprolol Succinate Extended Release 25 mg Tablets
Division: DIABGLYM
Composition
Each extended-release tablet contains:
Olmesartan Medoxomil IP — 20 mg
Metoprolol Succinate Extended Release IP equivalent to Metoprolol — 25 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Extended-release oral tablet
Product Description
OLMEROOT-MT 25 is a scientifically balanced antihypertensive combination of Olmesartan Medoxomil 20 mg and Metoprolol Succinate Extended Release 25 mg, formulated for the effective management of hypertension, coronary artery disease, and long-term cardiovascular risk reduction. This combination provides dual blood pressure control by combining the renin-angiotensin system blockade of Olmesartan with the cardioselective beta-blocking action of Metoprolol Succinate, resulting in superior blood pressure reduction and enhanced cardiovascular protection.
Olmesartan Medoxomil is a potent angiotensin II receptor blocker (ARB) that promotes vasodilation, reduces peripheral vascular resistance, and provides cardiovascular and renal protection. Metoprolol Succinate Extended Release is a long-acting beta-1 selective blocker that reduces heart rate, myocardial contractility, and cardiac workload while providing sustained 24-hour cardiovascular control.
OLMEROOT-MT 25 is particularly beneficial in patients with hypertension associated with tachycardia, coronary artery disease, diabetes, metabolic syndrome, left ventricular dysfunction, and high cardiovascular risk requiring combination antihypertensive therapy.
Technical Knowledge of Olmesartan Medoxomil and Metoprolol Succinate Extended Release
Olmesartan Medoxomil is a prodrug that is converted to Olmesartan, which selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction, aldosterone secretion, sympathetic activation, and vascular remodeling.
Metoprolol Succinate Extended Release selectively blocks beta-1 adrenergic receptors in the heart, reducing sympathetic stimulation, heart rate, myocardial contractility, and renin secretion. The extended-release formulation provides stable plasma concentrations and sustained therapeutic activity throughout the day.
The combination of Olmesartan and Metoprolol Succinate Extended Release provides complementary antihypertensive mechanisms with additional cardiovascular and renal protective benefits.
Mechanism of Action
Olmesartan blocks AT1 receptors, promotes vasodilation, reduces peripheral vascular resistance, decreases aldosterone secretion, improves vascular function, and protects cardiovascular and renal tissues.
Metoprolol Succinate Extended Release reduces heart rate, decreases myocardial contractility, lowers cardiac output, suppresses renin release, and reduces myocardial oxygen demand through sustained beta-1 receptor blockade.
Key Benefits
Effective reduction of systolic and diastolic blood pressure
Dual antihypertensive mechanism
Provides sustained 24-hour blood pressure control
Reduces heart rate and myocardial workload
Supports cardiovascular and renal protection
Improves vascular function and endothelial health
Helps prevent cardiovascular events
Suitable for long-term hypertension and cardiovascular management under medical supervision
Clinical Applications
OLMEROOT-MT 25 is commonly prescribed for essential hypertension, hypertension with tachycardia, hypertension with coronary artery disease, hypertension with diabetes mellitus, hypertension with chronic kidney disease, stable coronary artery disease, cardiovascular risk reduction, and long-term antihypertensive management.
Facts About Olmesartan Medoxomil and Metoprolol Succinate Extended Release
Olmesartan is a highly selective ARB with excellent antihypertensive efficacy and proven cardiovascular and renal protective benefits. Metoprolol Succinate Extended Release is a long-acting beta-blocker widely used in hypertension, ischemic heart disease, and heart failure. The combination provides comprehensive blood pressure control, heart rate reduction, and long-term cardiovascular protection with convenient once-daily dosing.
Key Facts
ARB and beta-blocker combination therapy
Olmesartan Medoxomil 20 mg for vascular and renal protection
Metoprolol Succinate Extended Release 25 mg for sustained heart rate and blood pressure control
Provides 24-hour antihypertensive action
Effective in hypertension and coronary artery disease
Evidence-based cardiovascular combination therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
OLMEROOT-MT 25 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, coronary artery disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination.
Why Choose OLMEROOT-MT 25 for PCD Pharma Franchise?
High prescription potential
Strong physician and cardiologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Olmesartan Medoxomil 20 mg and Metoprolol Succinate Extended Release 25 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented extended-release formulation
Controlled-release tablet manufacturing technology
Blister and Alu-Alu packaging options
OLMEROOT-MT 25 from DIABGLYM combines effective blood pressure control, sustained heart rate management, comprehensive cardiovascular and renal protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Olmesartan and Metoprolol formulation.
